ReviewWorld journal of hepatology2023
Noninvasive biomarkers in pediatric nonalcoholic fatty liver disease.
Review in World journal of hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07731360 (A Non-Invasive Diagnostic Panel for MASLD in Children With Obesity), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Non-Invasive Diagnostic Panel for MASLD in Children With Obesity: Evaluation of a Multiparametric Biomarker Panel and Genetic Risk Score Using LASSO-Regularized Logistic Regression - The PedMASLD-MultiOmics Pilot Study
Who cites it
16 citing papers in PubMed, 17 citations in OpenAlex.
- MASLD: Spatial Mechanisms and New Therapeutics.Biomolecules · 2026Review
- Longitudinal performance of vibration controlled transient elastography in pediatric metabolic dysfunction associated steatotic liver disease.Journal of pediatric gastroenterology and nutrition · 2026Article
- Hepatic Fat Quantification Using Beta Distribution and a Probabilistic Neural Network in a Prepubertal Male Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- Comparison of hepatic PDFF, T2*, and T2 estimates from breath-hold and free-breathing respiratory-gated MRI acquisitions in children and young adults.Abdominal radiology (New York) · 2026Article
- Nomogram integrating serological markers and clinical parameters for predicting severe hepatic steatosis in patients with abnormal glucose metabolism.Diabetology & metabolic syndrome · 2026Article
- Interplay of childhood metabolic dysfunction-associated steatotic liver disease and obesity in the development of youth-onset type 2 diabetes.World journal of clinical pediatrics · 2026Article
- Altered hepatic metabolism in Down syndrome.Cell reports · 2026Article
- Safety and diagnostic accuracy of ultrasound-assisted percutaneous liver biopsy in pediatric patients: a retrospective single-center study.Annals of gastroenterology · 2026Article
- Tryptophan derivatives as non-invasive diagnostic indicators for obesity-related MASLD in children and adolescents.Diabetes, obesity & metabolism · 2025Article
- Call to action-Pediatric MASLD requires immediate attention to curb health crisis.Hepatology (Baltimore, Md.) · 2025Review
- Metabolic dysfunction-associated steatotic liver disease (MASLD) in children with obesity: An Obesity Medicine Association (OMA) and expert joint perspective 2025.Obesity pillars · 2025Review
- The importance of elastography in hepatological diagnostics in children.Clinical and experimental hepatology · 2025Review
- Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives.Hepatology international · 2024Review
- Thrombospondin-2 as a potential noninvasive biomarker of hepatocyte injury but not liver fibrosis in children with MAFLD: A preliminary study.Clinical and experimental hepatology · 2023Article
- Neutrophils: tissue and circulating signatures of pediatric non-alcoholic fatty liver disease.Frontiers in cell and developmental biology · 2023Review
- Fungal signature differentiates alcohol-associated liver disease from nonalcoholic fatty liver disease.Gut microbesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease worldwide among children and adolescents. It encompasses a spectrum of disease, from its mildest form of isolated steatosis, to nonalcoholic steatohepatitis (NASH) to liver fibrosis and cirrhosis, or end-stage liver disease. The early diagnosis of pediatric NAFLD is crucial in preventing disease progression and in improving outcomes. Currently, liver biopsy is the gold standard for diagnosing NAFLD. However, given its invasive nature, there has been significant interest in developing noninvasive methods that can be used as accurate alternatives. Here, we review noninvasive biomarkers in pediatric NAFLD, focusing primarily on the diagnostic accuracy of various biomarkers as measured by their area under the receiver operating characteristic, sensitivity, and specificity. We examine two major approaches to noninvasive biomarkers in children with NAFLD. First, the biological approach that quantifies serological biomarkers. This includes the study of individual circulating molecules as biomarkers as well as the use of composite algorithms derived from combinations of biomarkers. The second is a more physical approach that examines data measured through imaging techniques as noninvasive biomarkers for pediatric NAFLD. Each of these approaches was applied to children with NAFLD, NASH, and NAFLD with fibrosis. Finally, we suggest possible areas for future research based on current gaps in knowledge.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.